Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 42,108,430 | 33,724,300 | 25,056,690 | 22,401,280 | 19,448,130 |
| Cost of Goods | 6,455,690 | 5,193,078 | 4,028,237 | 3,763,988 | 3,206,782 |
| Gross Profit | 35,652,750 | 28,531,220 | 21,028,450 | 18,637,290 | 16,241,340 |
| Operating Expenses | 17,044,280 | 13,637,550 | 10,435,730 | 9,308,020 | 7,950,020 |
| Operating Income | 18,609,150 | 14,893,750 | 10,592,950 | 9,330,261 | 8,292,104 |
| Interest Expense | 1,065,170 | 122,694 | 847,618 | 389,954 | 401,997 |
| Other Income | 898,720 | 427,614 | 33,848 | 459,321 | 249,409 |
| Pre-tax Income | 18,442,700 | 15,198,670 | 9,779,180 | 9,399,628 | 8,139,516 |
| Income Tax | 3,799,435 | 3,047,893 | 1,916,839 | 1,801,489 | 1,683,974 |
| Net Income Continuous | 14,643,260 | 12,150,770 | 7,862,340 | 7,598,139 | 6,455,542 |
| Net Income | $14,643,260 | $12,150,770 | $7,862,340 | $7,598,139 | $6,455,542 |
| EPS Basic Total Ops | 3.29 | 2.71 | 1.74 | 1.65 | 1.38 |
| EPS Basic Continuous Ops | 3.29 | 2.71 | 1.74 | 1.65 | 1.38 |
| EPS Diluted Total Ops | 3.28 | 2.70 | 1.73 | 1.65 | 1.38 |
| EPS Diluted Continuous Ops | 3.28 | 2.70 | 1.73 | 1.65 | 1.38 |
| EPS Diluted Before Non-Recurring Items | 3.28 | 2.70 | 1.73 | 1.65 | 1.38 |
| EBITDA(a) | $21,379,670 | $16,260,510 | $11,635,410 | $10,288,840 | $9,173,462 |